Based on the Trevi Therapeutics Inc stock forecast from 8 analysts, the average analyst target price for Trevi Therapeutics Inc is USD 13.43 over the next 12 months. Trevi Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Trevi Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Trevi Therapeutics Inc’s stock price was USD 5.40. Trevi Therapeutics Inc’s stock price has changed by -14.01% over the past week, +25.58% over the past month and +87.50% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Trevi Therapeutics Inc
No recent average analyst rating found for Trevi Therapeutics Inc
Company Overview Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Read Less
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central ...Read More
Frequently Asked Questions About Trevi Therapeutics Inc (TRVI) Stock
Based on ratings from 8 analysts Trevi Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 15 buy, sell and hold ratings.
Unfortunately we do not have enough data on TRVI's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for TRVI is USD 13.43 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on TRVI's stock to indicate if its overvalued.
The last closing price of TRVI's stock was USD 5.40.
The most recent market capitalization for TRVI is USD 0.38B.
Based on targets from 8 analysts, the average taret price for TRVI is projected at USD 13.43 over the next 12 months.
This means that TRVI's stock price may go up by +148.68% over the next 12 months.
We can't find any ETFs which contains Trevi Therapeutics Inc's stock.
As per our most recent records Trevi Therapeutics Inc has 27 Employees.
Trevi Therapeutics Inc's registered address is 195 Church Street, New Haven, CT, United States, 06510.
You can get more information about it from Trevi Therapeutics Inc's website at https://www.trevitherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Trevi Therapeutics Inc (TRVI) Stock
Based on ratings from 8 analysts Trevi Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 15 buy, sell and hold ratings.
Unfortunately we do not have enough data on TRVI's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for TRVI is USD 13.43 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on TRVI's stock to indicate if its overvalued.
The last closing price of TRVI's stock was USD 5.40.
The most recent market capitalization for TRVI is USD 0.38B.
Based on targets from 8 analysts, the average taret price for TRVI is projected at USD 13.43 over the next 12 months.
This means that TRVI's stock price may go up by +148.68% over the next 12 months.
We can't find any ETFs which contains Trevi Therapeutics Inc's stock.
As per our most recent records Trevi Therapeutics Inc has 27 Employees.
Trevi Therapeutics Inc's registered address is 195 Church Street, New Haven, CT, United States, 06510.
You can get more information about it from Trevi Therapeutics Inc's website at https://www.trevitherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TRVI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
